- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01669941
Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya (STOP MiP KENYA)
Intermittent Screening and Treatment (IST) or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya: a Randomized Controlled Trial
Malaria in pregnancy (MiP) due to Plasmodium falciparum infection is a major cause of maternal morbidity and poor birth outcomes. Intermittent preventive treatment in pregnancy (IPTp) with Sulfadoxine pyrimethamine (SP), the administration of SP at predefined intervals in the second and third trimesters of pregnancy irrespective of the presence of malaria parasitemia, is currently recommended for HIV-negative women in all areas with stable moderate to high transmission of malaria. Due to increasing resistance to SP, it is no longer used as a treatment for symptomatic malaria, and the efficacy of IPTp-SP seems to be decreased. This study aims to look at a new drug, Dihydroartemisinin-Piperaquine (DP) for IPTp, as well as to explore the strategy of intermittent screening and treatment in pregnancy (ISTp) with DP. This strategy uses increased screening at time of focused antenatal care (FANC) with treatment of women who screen positive.
The hypothesis is that the efficacy of both IPTp-DP and ISTp-DP will be associated with a reduction in malaria infection at delivery among HIV(-) women when compared to IPTp-SP, in an area with decreasing malaria transmission and high levels of SP resistance in Kenya.
Study Overview
Status
Intervention / Treatment
Detailed Description
Malaria in pregnancy (MiP) due to Plasmodium falciparum infection is a major cause of maternal morbidity and poor birth outcomes. Pregnant women are at increased risk of more frequent and severe malaria infections than are non-pregnant women. Intermittent preventive treatment in pregnancy (IPTp), the administration of treatment doses of an antimalarial at predefined intervals in the second and third trimesters of pregnancy irrespective of the presence of malaria parasitemia, is currently recommended for HIV-negative women in all areas with stable moderate to high transmission of malaria. The strategy is thought to work by providing intermittent clearance or suppression of parasites in the placenta, and preventing new infections from occurring through the prophylactic effect of the recommended drug for IPTp, sulfadoxine-pyrimethamine (SP).
SP is the only drug currently used for IPTp. Due to increasing resistance to SP, it is no longer used as a treatment for symptomatic malaria, however, IPTp with SP remains effective even in areas where SP resistance in children under five (determined by in vivo efficacy studies) is up to 26%. SP therefore continues to be used for IPTp in many countries where it is no longer used for treatment of symptomatic malaria. However, more recent data from northern Tanzania and Malawi indicate that at higher rates of resistance, IPTp-SP may no longer be effective, and could potentially be harmful.
In view of this data, a search for alternatives to IPTp-SP is warranted. One strategy would be to choose a different drug for IPTp. Of the available combinations, Dihydroartemisinin-Piperaquine (DP) remains one of the most attractive options because of the long half-life of piperaquine (PQ) and the demonstrated efficacy and safety in pregnancy. Another strategy to consider is intermittent screening and treatment in pregnancy (ISTp), whereby there is increased screening at time of focused antenatal care (FANC) with treatment of women who screen positive. The same properties (long half-life, tolerability, safety, once daily dosing) which make DP a good choice for IPTp also make it one of the best available options for ISTp.
This study aims to compare the efficacy of IPTp-SP against that of IPTp-DP and ISTp-DP to determine if these alternate strategies are associated with a reduction in malaria infection at delivery among HIV(-) women in an area with decreasing malaria transmission and high levels of SP resistance in Kenya.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Bondo, Kenya, 40601
- Bondo District Hospital
-
Madiany, Kenya
- Madiany sub-District Hospital
-
-
Nyanza
-
Rarieda, Nyanza, Kenya
- Lwak Mission Hospital
-
Siaya, Nyanza, Kenya, 40600
- Siaya District Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Viable pregnancy assessed by Doppler
- Gestational age 16 to 32 weeks (inclusive) by fundal height
- No history of IPTp use during this pregnancy
- Willing to participate and complete the study schedule
- Willing to sign or thumb print informed consent
- Resident of study area and intending to stay in the area for the duration of the follow-up
- Willing to deliver in the labor ward of the study clinic or hospital
- HIV negative at enrolment
Exclusion Criteria:
- HIV positive or unknown
- Residence outside study area or planning to move out in the 12 months following enrolment
- High risk pregnancy, including any pre-existing illness likely to cause complication of pregnancy (hypertension, diabetes, asthma, epilepsy, renal disease, liver disease, fistula repair, leg or spine deformity)
- Severe anemia requiring blood transfusion (Hb ≤ 7.0 g/dL) at enrolment
- Known allergy or previous adverse reaction to any of the study drugs
- Unable to give informed consent (for example due to mental disability)
- Previous inclusion in the same study
- Gestational age >32 weeks
- Previous IPTp during the current pregnancy
- Participating in other malaria intervention studies
- Known or suspected cardiac disease
- Patients taking drugs in any of the following classes: antiarrhythmic agents, neuroleptics, macrolides, and certain antimalarial drugs such as mefloquine, chloroquine, halofantrine and lumefantrine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IPTp-DP
At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more.
The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
|
At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more.
The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
Other Names:
|
EXPERIMENTAL: ISTp-DP
At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P.
falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP).
Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine.
Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more.
The first dose will be observed; the woman will be given the additional 2 doses to take at home
|
At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P.
falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine.
Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine.
Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more.
The first dose will be observed; the woman will be given the additional 2 doses to take at home
Other Names:
|
ACTIVE_COMPARATOR: IPTp-SP
Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit.
This is the standard regimen.
|
3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maternal malaria at delivery
Time Frame: Delivery
|
Active or recent infection at delivery measured as the composite of peripheral and placental malaria, detected by: positive peripheral blood smear or RDT or positive placental smear, RDT, or histopathology
|
Delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decreased fetal morbidity
Time Frame: Delivery
|
Decreased fetal morbidity, defined as the composite of any of the following:
|
Delivery
|
Frequency of fetal congenital malformations
Time Frame: At delivery
|
At delivery
|
|
Pharmacokinetics- piperaquine level
Time Frame: At baseline, and day 2 and day 7 following dosing.
|
At baseline, and day 2 and day 7 following dosing.
|
|
level of antibodies to variant surface antigens (VSAs)
Time Frame: At delivery
|
At delivery
|
|
Frequency of maternal adverse events
Time Frame: At each ANC visit and at delivery
|
At each ANC visit and at delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Meghna Desai, PhD MPH, Centers for Disease Control and Prevention
- Principal Investigator: Abraham Katana, MD, Kenya Medical Research Institute
Publications and helpful links
General Publications
- Chotsiri P, Gutman JR, Ahmed R, Poespoprodjo JR, Syafruddin D, Khairallah C, Asih PBS, L'lanziva A, Otieno K, Kariuki S, Ouma P, Were V, Katana A, Price RN, Desai M, Ter Kuile FO, Tarning J. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01150-20. doi: 10.1128/AAC.01150-20. Print 2021 Feb 17.
- Desai M, Gutman J, L'lanziva A, Otieno K, Juma E, Kariuki S, Ouma P, Were V, Laserson K, Katana A, Williamson J, ter Kuile FO. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015 Dec 19;386(10012):2507-19. doi: 10.1016/S0140-6736(15)00310-4. Epub 2015 Sep 28.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STOPMiP-KENYA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Turku University HospitalUniversity of TurkuCompleted
-
Hopital Antoine BeclereUnknown
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
Clinical Trials on IPTp-DP
-
JhpiegoBarcelona Institute for Global HealthCompletedMalaria in PregnancyCongo, The Democratic Republic of the, Madagascar, Mozambique, Nigeria
-
Kamuzu University of Health SciencesUnited States Agency for International Development (USAID); Centers for Disease... and other collaboratorsCompleted
-
Vidya RamanCompletedCryptorchidism | Hypospadias | Tonsillar Hypertrophy | Hydrocele | Adenoid HypertrophyUnited States
-
Neurolief Ltd.Active, not recruiting
-
Galderma R&DCompletedGlabellar Frown Lines | Canthal LinesUnited States
-
AgonOx, Inc.Providence St Joseph Health; Phio Pharmaceuticals Corp.RecruitingMelanoma | Gynecologic Cancer | Colorectal Cancer | Lung Cancer | HNSCC | Urogenital CancerUnited States
-
D-Pharm Ltd.CompletedStroke | Cerebrovascular Disorders | Brain IschemiaIsrael, Germany
-
ReNeuron LimitedCompletedCerebral Infarction | Hemiparesis | Ischaemic Stroke | Arm ParalysisUnited Kingdom
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingIntraoperative Hemodyamic MonitoringItaly